Observations of high-latitude geomagnetic field fluctuations during St. Patrick’s Day storm: Swarm and SuperDARN measurements

The aim of this work is to study the properties of the magnetic field’s fluctuations produced by ionospheric and magnetospheric electric currents during the St. Patrick’s Day geomagnetic storm (17 March 2015). We analyse the scaling features of the external contribution to the horizontal geomagnetic field recorded simultaneously by thethree satellites of the Swarm constellation during a period of 13 days (13–25 March 2015). We examine the different latitudinal structure of the geomagnetic field fluctuations and analyse the dynamical changes in the magnetic field scaling features during the development of the geomagnetic storm. Analysis reveals consistent patterns in the scaling properties of magnetic fluctuations and striking changes between the situation before the storm, during the main phase and recovery phase. We discuss these dynamical changes in relation to those of the overall ionospheric polar convection and potential structures as reconstructed using SuperDARN data. Our findings suggest that distinct turbulent regimes characterised the mesoscale magnetic field’s fluctuations and that some factors, which are known to influence large-scale fluctuations, have also an influence on mesoscale fluctuations. The obtained results are an example of the capability of geomagnetic field fluctuations data to provide new insights about ionospheric dynamics and ionosphere–magnetosphere coupling. At the same time, these results could open doors for development of new applications where the dynamical changes in the scaling features of the magnetic fluctuations are used as local indicators of magnetospheric conditions.Published1051A. Geomagnetismo e PaleomagnetismoJCR Journa

Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone

BACKGROUND: The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate. METHODS: In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in the year before randomization but not during the previous month. Patients were excluded from the trial if they had a history of life-threatening or unstable asthma. The primary safety end point was the first serious asthma-related event (death, endotracheal intubation, or hospitalization). Noninferiority of fluticasone-salmeterol to fluticasone alone was defined as an upper boundary of the 95% confidence interval for the risk of the primary safety end point of less than 2.0. The efficacy end point was the first severe asthma exacerbation. RESULTS: Of 11,679 patients who were enrolled, 67 had 74 serious asthma-related events, with 36 events in 34 patients in the fluticasone-salmeterol group and 38 events in 33 patients in the fluticasone-only group. The hazard ratio for a serious asthma-related event in the fluticasone-salmeterol group was 1.03 (95% confidence interval [CI], 0.64 to 1.66), and noninferiority was achieved (P=0.003). There were no asthma-related deaths; 2 patients in the fluticasone-only group underwent asthma-related intubation. The risk of a severe asthma exacerbation was 21% lower in the fluticasone-salmeterol group than in the fluticasone-only group (hazard ratio, 0.79; 95% CI, 0.70 to 0.89), with at least one severe asthma exacerbation occurring in 480 of 5834 patients (8%) in the fluticasone-salmeterol group, as compared with 597 of 5845 patients (10%) in the fluticasone-only group (P<0.001). CONCLUSIONS: Patients who received salmeterol in a fixed-dose combination with fluticasone did not have a significantly higher risk of serious asthma-related events than did those who received fluticasone alone. Patients receiving fluticasone-salmeterol had fewer severe asthma exacerbations than did those in the fluticasone-only group